X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
What has fuelled pharma stocks? 
(Tue, 28 Sep Pre-Open) 
 
The BSE Healthcare index has outperformed the Sensex in the past one year. While the same has been due to the overall buoyancy in the Indian stockmarkets, ramp up in performance has also led to investors flocking to pharma stocks.

Data Source: Prowess


For starters, there was a sharp reversal in fortunes of Indian pharma companies in the past one year as compared to FY09. In FY09 for instance, there were a host of problems plaguing pharma companies. First of all, they had to deal with higher receivables in semi-regulated markets as a result of which sales were hampered. Not just that weaker environment in the US and Europe and fewer approvals meant that sales from these regions also took a beating. Since then, however, there has been growth in sales on the back of more approvals and a consequent increase in product launches in the global generics market.

That said, while the generics business has seen good growth, the same cannot be said for custom manufacturing (for global innovators). With the US and Europe still mired in a slump, many of these global innovators were wary of outsourcing. But the pressure to cut costs means that the case for outsourcing in the longer run remains strong. Operating margins saw an improvement on the back of an improved product mix. Absence of forex volatility (of the kind seen in FY09) meant that Indian companies did not have to report massive forex losses.

The outlook for the pharma sector remains healthy. Drugs worth billions of dollars are scheduled to lose patents till 2013. Hence the opportunity is immense despite intense competition and price erosion. Those focusing on niche products with limited completion will have the edge. The prospects in the domestic market also look good. Although the landscape has been changing on account of a spate of acquisitions made by global innovators in India. At the end of the day, while the outlook for the overall sector is strong, the strategies adopted by various companies to maximize revenues and profits will determine which company will come out on the top.

As far as valuations are concerned, prices of many pharma stocks have run up. And so, quite a few stocks appear expensive. But we urge investors not to get carried away by the overall euphoria that has surrounded the pharma sector. Instead they should take a stock specific approach while investing in the sector.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "What has fuelled pharma stocks?". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE SENSEX


Jul 21, 2017 (Close)

MARKET STATS